Arcutis Biotherapeutics expects significant revenue growth in Q4 and full-year 2024.

From GlobeNewswire: 2025-01-12 08:30:00

Arcutis Biotherapeutics, Inc. announced preliminary unaudited financial information for Q4 2024 and the full year. Q4 product revenue is expected to be $63 million, up 366% from Q4 2023. Full-year revenue is expected to be $160 million, up 449% from 2023. Cash and marketable securities as of Dec 31, 2024, are approximately $229 million. The company will release complete financial results on Feb 25, 2025. President and CEO Frank Watanabe highlighted strong sales momentum and revenue growth driven by demand for ZORYVE products. Management will host investor meetings around the J.P. Morgan Healthcare Conference.



Read more at GlobeNewswire: Arcutis Announces Preliminary Unaudited Fourth Quarter